Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
user
  1. Dashboard
  2. My Profile
  3. My Address
  4. My Orders
  5. Acro Membership
Login Register
Promotion
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
TL1A Hot |GMP Cytokines Hot |FcRn Binding Kit (TR-FRET) New |Claudin 18.2
0
There is no goods in the shopping cart !
My Cart|Secure Checkout
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > PSMA

PSMA

Brief Information

Name:Prostate-Specific Membrane Antigen
Target Synonym:EC:3.4.17.21,GIG27,Glutamate carboxypeptidase II,NAALADase I,FOLH,Cell growth-inhibiting gene 27 protein,PSM,N-acetylated-alpha-linked acidic dipeptidase I,GCPII,Folylpoly-gamma-glutamate carboxypeptidase,Folate hydrolase 1,FOLH1,Pteroylpoly-Gamma-Glutamate Carboxypeptidase,Membrane Glutamate Carboxypeptidase,Glutamate Carboxypeptidase 2,Glutamate Carboxylase II,NAALAD1,FGCP,PSMA,MGCP,Folate Hydrolase (Prostate-Specific Membrane Antigen) 1,N-Acetylated Alpha-Linked Acidic Dipeptidase 1,Prostate
Number of Launched Drugs:5
Number of Drugs in Clinical Trials:72
Lastest Research Phase:Approved

Product ListCompare or Buy

Product> Filter Results
By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
CHEK-ATP185 Human HEK293/Human PSMA Stable Cell Line
PSA-M82F3 Mouse Biotinylated Mouse PSMA / FOLH1 Protein, Fc,Avitag™ (MALS verified)
PSA-M82F3-structure
PSA-M82F3-sds
PSA-M82Q4 Mouse Biotinylated Mouse PSMA / FOLH1 Protein, His,Avitag™
PSA-M82Q4-sds
PSA-M5266 Mouse Mouse PSMA / FOLH1 Protein, Fc Tag (MALS verified)
PSA-M5266-structure
PSA-M5266-sds
PSA-H82F7 Human Biotinylated Human PSMA / FOLH1 Protein, Fc,Avitag™ (MALS verified)
PSA-H82F7-structure
PSA-H82F7-sds
PSA-C82Q6 Cynomolgus Biotinylated Cynomolgus PSMA / FOLH1 Protein, His,Avitag™ (MALS verified)
PSA-C82Q6-structure
PSA-C82Q6-sds
PSA-R5245 Rat Rat PSMA / FOLH1 Protein, His Tag (active enzyme, MALS verified)
PSA-R5245-structure
PSA-R5245-sds
PSA-HP2Q3 Human PE-Labeled Human PSMA / FOLH1 Protein, His Tag (Site-specific conjugation)
PSA-HP2Q3-structure
MBP-K007 Human Human PSMA-coupled Magnetic Beads
PSA-H5264 Human Human PSMA / FOLH1 Protein, Fc Tag, premium grade
PSA-H5264-structure
PSA-H5264-sds
PSA-M5245 Mouse Mouse PSMA / FOLH1 Protein, His Tag (active enzyme) (MALS verified)
PSA-M5245-structure
PSA-M5245-sds
PSA-C5247 Cynomolgus Cynomolgus PSMA / FOLH1 Protein, His Tag (active enzyme, MALS verified)
PSA-C5247-structure
PSA-C5247-sds
PSA-HF244 Human FITC-Labeled Human PSMA / FOLH1 Protein, His Tag
PSA-HF244-structure
PSA-HF244-sds
PSA-H82Qb Human Biotinylated Human PSMA / FOLH1 Protein, His,Avitag™, premium grade
PSA-H82Qb-structure
PSA-H82Qb-sds
PSA-H52H3 Human Human PSMA / FOLH1 Protein, His Tag (active enzyme, MALS verified)
PSA-H52H3-structure
PSA-H52H3-sds
ACRO Quality

Part of Bioactivity data

CHEK-ATP185-Cell-based assay
PSMA FACS

Expression analysis of human PSMA on HEK293/Human PSMA Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human PSMA Stable Cell Line or negative control cell using PE anti-human PSMA antibody after fixation with 4% paraformaldehyde.

Protocol
PSA-HP2Q3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

5e5 of anti-PSMA CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human PSMA, His Tag (Cat. No. PSA-HP2Q3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

Protocol
PSA-C82Q6-ELISA
PSMA ELISA

Immobilized Monoclonal Anti-Human PSMA Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind Biotinylated Cynomolgus PSMA Protein, His,Avitag (Cat. No. PSA-C82Q6) with a linear range of 0.5-16 ng/mL (QC tested).

Protocol
PSA-M82F3-MALS-HPLC
PSMA MALS images

The purity of Biotinylated Mouse PSMA Protein, Fc,Avitag (Cat. No. PSA-M82F3) is more than 85% and the molecular weight of this protein is around 230-260 kDa verified by SEC-MALS.

Customer Reviews

Synonym Name

FOLH1,PSMA,GIG27,FOLH,NAALAD1,PSM,NAALADase I,GCPII,FGCP

Background

The biotinylated PSMA protein was conjugated to streptavidin magnetic beads. This pre-coupled magnetic bead product can capture the anti-PSMA antibody from various assay systems. The beads are in uniform size, narrow size distribution with large surface area and unique surface coating, which can help you get the best performance and highly reproducible results. This PSMA coupled magnetic beads will bring great convenience with minimum non-specific binding and developed protocols. This ready-to-use product could greatly save your time and hassle.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Capromab pendetide lndium-CYT-356; Indium-111-CYT-356; CYT-356; 111In CYT-356 Approved Eusa Pharma ProstaScint United States Prostatic Neoplasms Cytogen Corp 1996-10-28 Prostatic Neoplasms Details
Piflufolastat F 18 Approved Johns Hopkins University Pylarify, Pylclari United States Prostatic Neoplasms Progenics Pharmaceuticals Inc 2021-05-26 Carcinoma, Renal Cell; Pancreatic Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Genital Neoplasms, Female; Diagnostic agents; Adenocarcinoma; Carcinoma, Hepatocellular; Neoplasm Metastasis Details
Ga-68 PSMA-11 Ga-68-PSMA-11; Ga-68-PSMA; 68Ga-HBED-CC-PSMA11; AAA517; AAA-517 Approved Radiomedix Inc Gallium Ga 68 Psma-11, Illuccix, ILLUCCIX, Locametz United States Prostatic Neoplasms Telix Pharmaceuticals Ltd, University Of California, Los Angeles 2020-12-01 Neoplasm Recurrence, Local; Solid tumours; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Diagnostic agents; Neoplasm Metastasis; Carcinoma, Hepatocellular Details
Lutetium (177Lu) vipivotide tetraxetan Lutetium-177-PSMA-617; PSMA-617-[177Lu]; 177-Lu-PSMA-617; AAA-617; Lu-177- RLT Approved Radiomedix Inc PLUVICTO United States Prostatic Neoplasms, Castration-Resistant Novartis Pharmaceuticals Corp 2022-03-23 Carcinoma, Verrucous; Prostatic Neoplasms, Castration-Resistant; Carcinoma, Adenoid Cystic; Prostatic Neoplasms; Carcinoma, Squamous Cell; Neoplasm Metastasis Details
Flotufolastat F-18 Fluorine-18 rhPSMA; rhPSMA-7.3 (18F); 18F-rhPSMA-7.3; (18F)-rhPSMA-7.3; 18FrhPSMA-7.3; F-18-rhPSMA-7.3 Approved Blue Earth Diagnostics Inc, Technical University Munich POSLUMA United States Prostatic Neoplasms Blue Earth Diagnostics Ltd 2023-05-25 Prostatic Neoplasms; Contrast agents Details
Capromab pendetide lndium-CYT-356; Indium-111-CYT-356; CYT-356; 111In CYT-356 Approved Eusa Pharma ProstaScint United States Prostatic Neoplasms Cytogen Corp 1996-10-28 Prostatic Neoplasms Details
Piflufolastat F 18 Approved Johns Hopkins University Pylarify, Pylclari United States Prostatic Neoplasms Progenics Pharmaceuticals Inc 2021-05-26 Carcinoma, Renal Cell; Pancreatic Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Genital Neoplasms, Female; Diagnostic agents; Adenocarcinoma; Carcinoma, Hepatocellular; Neoplasm Metastasis Details
Ga-68 PSMA-11 Ga-68-PSMA-11; Ga-68-PSMA; 68Ga-HBED-CC-PSMA11; AAA517; AAA-517 Approved Radiomedix Inc Gallium Ga 68 Psma-11, Illuccix, ILLUCCIX, Locametz United States Prostatic Neoplasms Telix Pharmaceuticals Ltd, University Of California, Los Angeles 2020-12-01 Neoplasm Recurrence, Local; Solid tumours; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Diagnostic agents; Neoplasm Metastasis; Carcinoma, Hepatocellular Details
Lutetium (177Lu) vipivotide tetraxetan Lutetium-177-PSMA-617; PSMA-617-[177Lu]; 177-Lu-PSMA-617; AAA-617; Lu-177- RLT Approved Radiomedix Inc PLUVICTO United States Prostatic Neoplasms, Castration-Resistant Novartis Pharmaceuticals Corp 2022-03-23 Carcinoma, Verrucous; Prostatic Neoplasms, Castration-Resistant; Carcinoma, Adenoid Cystic; Prostatic Neoplasms; Carcinoma, Squamous Cell; Neoplasm Metastasis Details
Flotufolastat F-18 Fluorine-18 rhPSMA; rhPSMA-7.3 (18F); 18F-rhPSMA-7.3; (18F)-rhPSMA-7.3; 18FrhPSMA-7.3; F-18-rhPSMA-7.3 Approved Blue Earth Diagnostics Inc, Technical University Munich POSLUMA United States Prostatic Neoplasms Blue Earth Diagnostics Ltd 2023-05-25 Prostatic Neoplasms; Contrast agents Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
18F-PSMA-1007 18F-PSMA-1007 Phase 3 Clinical Deutsches Krebsforschungszentrum Neoplasms; Prostatic Neoplasms Details
Gallium-68 PSMA-617 225 Ac-PSMA-617; 68Ga-PSMA-617; 68Ga-DKFZ-617; 68Ga-DKFZ-PSMA -617; Gallium-68-PSMA-617; PSMA-617-[68Ga]; 68Ga-DOTA-PSMA-DKFZ -617 Phase 3 Clinical Peking Union Medical College Hospital Carcinoma, Adenoid Cystic; Prostatic Neoplasms Details
Fluorine-18-CTT-1057 CTT-1057; 18F-CTT1057; CTT-1057-18F; CTT-1057-F-18 Phase 3 Clinical Washington University, Cancer Targeted Technology Llc Recurrence; Carcinoma, Renal Cell; Prostatic Neoplasms Details
ITM-24D ITM-24D; 68Ga-PSMA-TTM Phase 3 Clinical ITM Isotope Technologies Munich SE Prostatic Neoplasms Details
18F vipivotide tetraxetan 18F-PSMA-617; Al18F-PSMA-617 Phase 3 Clinical Peking Union Medical College Hospital Prostatic Neoplasms Details
64Cu-PSMA I&T Copper Cu 64 PSMA I&T; Cu-64-PSMA-I&T; 64-Copper-PSMA-I&T; Copper-64-prostate specific membrane antigen I&T Phase 3 Clinical Curium Us Llc Prostatic Neoplasms Details
Thretide[18F] Phase 3 Clinical Shanghai Lannacheng Biotechnology Co Ltd Neoplasms; Prostatic Neoplasms; Diagnostic agents Details
64Cu-SAR-bisPSMA (Clarity Pharmaceuticals) Phase 3 Clinical Clarity Pharmaceuticals Ltd Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
177Lu-DOTA-rosopatamb 177Lu-DOTA-TLX591-CHO; TLX591 Phase 3 Clinical Telix Pharmaceuticals Ltd Prostatic Neoplasms Details
[Lu177]-PNT-2002 PNT-2002 Phase 3 Clinical Carcinoma, Adenoid Cystic; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
Lutetium-177-PSMA-I&T Phase 2 Clinical Radboud University Nijmegen Salivary Gland Neoplasms; Carcinoma, Adenoid Cystic; Prostatic Neoplasms Details
68Ga-PSMA-R2 (Advanced Accelerator Applications SA) Phase 2 Clinical Advanced Accelerator Applications Sa Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
177Lu-PSMA-R2 177Lu-PSMA-R2; 177Lu-PSMA-SR6; AAA-602 Phase 2 Clinical Advanced Accelerator Applications Sa Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
89Zr-DFO-huJ591 Zr89-J591; 89Zr-DFO-J591; 89Zr-DFO-huJ591 Phase 2 Clinical Memorial Sloan Kettering Cancer Center Prostatic Neoplasms Details
Nezastomig REGN-5678 Phase 2 Clinical Carcinoma, Renal Cell; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
225Ac-J591 225Ac-DOTA-J591; 225Ac-J591; CONV 01-α Phase 2 Clinical Cornell University Prostatic Neoplasms Details
ATL-101 MLN-591RL; ATL-101; huJ-591; MLN-591; J-591; Lu-177-J591; 177Lu-J591; 90Y-J591; muJ-591 Phase 2 Clinical Weill Medical College of Cornell University Ovarian Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung Details
[131I]MIP-1095 1095; [131I]MIP-1095; [131I]MIP-1466 Phase 2 Clinical Progenics Pharmaceuticals Inc Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
CONV-01-alpha + PSMA I&T Phase 2 Clinical Convergent Therapeutics Inc Prostatic Neoplasms Details
LAVA-1207 LAVA-1207 Phase 2 Clinical Vu University Medical Center, Lava Therapeutics NV Prostatic Neoplasms, Castration-Resistant Details
4SCAR-PSMA T cell therapy (Shenzhen Geno-Immune Medical Institute) Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Lymphoma, B-Cell; Neoplasms Details
[225Ac]Ac-PSMA-R2 [225Ac]Ac-PSMA-R2 Phase 2 Clinical Novartis Pharma Ag Prostatic Neoplasms, Castration-Resistant Details
177Lu-PSMA 177Lu-PSMA Phase 2 Clinical Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori Carcinoma, Renal Cell; Neoplasms; Prostatic Neoplasms; Neoplasm Metastasis Details
[177Lu]JH020002 Lu 177 JH020002; [177Lu]JH020002; 177-Lu JH-020002 Phase 2 Clinical Bivision Biomedical Technology (Nanjing) Co Ltd Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
[177Lu]Lu-XT033 [177Lu]Lu-XT033 Phase 2 Clinical Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
177Lu-HTK03170 177Lu-HTK03170 Phase 2 Clinical British Columbia Cancer Agency Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
Ga-68-NGUL Phase 2 Clinical Cellbion Co Ltd Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Lymphoma, B-Cell; Leukemia, B-Cell Details
GD2/PSMA Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) bi-4SCAR GD2/PSMA Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Solid tumours Details
PSMA/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) bi-4SCAR PSMA/CD70 Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Neoplasms Details
177Lu-rhPSMA-10.1 177Lu-rhPSMA10.1; (177Lu) rhPSMA-10.1; Lutetium (177Lu) rhPSMA-10.1 (Tx IMP); Lutetium-177 rhPSMA10.1; Lutetium Lu 177 PSMA-10.1; 177Lu rhPSMA-10.1; Lu177-rhPSMA; 177Lu Radiohybrid PSMA-10.1; 177Lu-rhPSMA-10.1; 177Lu-rhPSMA Phase 2 Clinical Technical University Munich Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Urogenital Neoplasms; Prostatic Diseases Details
Lu-177-DGUL PSMA-D GUL; Lu-177-DGUL; 177Lu-DOTA-GUL Phase 2 Clinical Cellbion Co Ltd Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
TLX-592 TLX-592 Phase 2 Clinical Telix Pharmaceuticals Ltd Prostatic Neoplasms Details
68Ga-PSMA-IRDye TLX591-Sx Phase 2 Clinical Telix Pharmaceuticals Ltd Prostatic Neoplasms Details
REGN-4336 REGN-4336 Phase 2 Clinical Prostatic Neoplasms, Castration-Resistant Details
[177Lu]Ludotadipep 177Lu-FC705; 177Lu-FC-705 Phase 2 Clinical Futurechem Prostatic Neoplasms, Castration-Resistant Details
67Cu-SAR-bisPSMA (Clarity Pharmaceuticals) Phase 2 Clinical Clarity Pharmaceuticals Ltd Prostatic Neoplasms, Castration-Resistant Details
ARX-517 ARX-517; ARX517 Phase 2 Clinical Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
OTL-78 OTL-78 Phase 2 Clinical Purdue University, Novartis Pharma Ag Prostatic Neoplasms Details
INO-5401 INO-5401 Phase 2 Clinical Inovio Pharmaceuticals Inc Carcinoma, Transitional Cell; Glioblastoma Details
225 Actinium PSMA-617 225 Actinium PSMA-617; 225Ac-PSMA 617; AAA 817; 225Ac-PSMA-617 Phase 1 Clinical Novartis Pharma Ag, Endocyte Inc, Advanced Accelerator Applications Sa Prostatic Neoplasms, Castration-Resistant Details
JNJ-63898081 JNJ-8081; JNJ-63898081 Phase 1 Clinical Johnson & Johnson Innovative Medicine Neoplasms Details
P28z-CAR P28z-CAR Phase 1 Clinical Memorial Sloan Kettering Cancer Center, United States Department Of Defense Prostatic Neoplasms Details
PSMA-CART cell therapy (Shanghai Bioray Laboratory) Phase 1 Clinical BRL Medicine Inc Prostatic Neoplasms, Castration-Resistant Details
Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center Phase 1 Clinical Roger Williams Medical Center Prostatic Neoplasms Details
CC-1 CC-1 Phase 1 Clinical University Of Tubingen, German Cancer Research Center (Dkfz) Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Carcinoma, Squamous Cell Details
Acapatamab AMG-160 Phase 1 Clinical Amgen Inc Prostatic Neoplasms, Castration-Resistant; Carcinoma, Non-Small-Cell Lung Details
177Lu-EB-vipivotide tetraxetan 177-Lu-EB-PSMA-617 Phase 1 Clinical Peking Union Medical College Hospital, National Institute For Biomedical Imaging And Bioengineering (Nibib) Carcinoma, Renal Cell; Carcinoma, Adenoid Cystic; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
[177Lu]-CTT-1403 CTT-1403; [177Lu]CTT1403; 177Lutetium CTT1403; [177Lu]CTT-1403 Phase 1 Clinical Cancer Targeted Technology Llc Prostatic Neoplasms Details
Pelgifatamab corixetan BAY-2315497 Phase 1 Clinical Bayer AG Prostatic Neoplasms, Castration-Resistant Details
161Tb-SibuDAB Phase 1 Clinical University Hospital Basel Prostatic Neoplasms, Castration-Resistant Details
[Ac-225]-PSMA-62 [Ac-225]-PSMA-62 Phase 1 Clinical Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
JNJ-9401 JNJ-9401 Phase 1 Clinical Xencor Inc Prostatic Neoplasms Details
ABBV-969 ABBV-969; ABBV969 Phase 1 Clinical Abbvie Inc, Immunogen Inc Prostatic Neoplasms, Castration-Resistant Details
JNJ-87189401 JNJ-87189401 Phase 1 Clinical Janssen Research & Development Llc Prostatic Neoplasms Details
Actinium-225-macropa-pelgifatamab BAY-3546828; BAY3546828 Phase 1 Clinical Bayer AG Prostatic Neoplasms, Castration-Resistant Details
177Lu-LNC1003 177Lu-LNC1003 Phase 1 Clinical Shanghai Lannacheng Biotechnology Co Ltd Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
PSMA-Targeted [In-111]-Labeled Trillium Compound Phase 1 Clinical Ratio Therapeutics Inc Prostatic Neoplasms Details
Autologous T cells therapy(Unicar-Therapy) Phase 1 Clinical Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Prostatic Neoplasms Details
212Pb-NG001 212Pb-NG001; AB-001; AB001 Phase 1 Clinical ARTBIO Inc Prostatic Neoplasms, Castration-Resistant Details
CART-PSMA cells（Nova Therapeutics） Phase 1 Clinical Nova Therapeutics LLC Prostatic Neoplasms Details
68Ga-labeled NY108 68-Ga-labeled NY-108 Phase 1 Clinical Prostatic Neoplasms Details
JANX-007 JANX-007; PSMA-TRACTr Phase 1 Clinical Janux Therapeutics Inc Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
JNJ-80038114 JNJ-80038114 Phase 1 Clinical Janssen Research & Development Llc Prostatic Neoplasms Details
CART-PSMA-TGFbRDN (University of Pennsylvania) Phase 1 Clinical University Of Pennsylvania Prostatic Neoplasms Details
TNB-585 TNB-585; AMG-340 Phase 1 Clinical Teneobio Inc Prostatic Neoplasms, Castration-Resistant Details
AVC-102 AVC-102 Phase 1 Clinical AvenCell Therapeutics Inc Kidney Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
CBP-1018 CBP-1018 Phase 1 Clinical Solid tumours; Carcinoma, Renal Cell; Prostatic Neoplasms; Lung Neoplasms Details
CCW-702 CCW-702 Phase 1 Clinical The Scripps Research Institute Inc, Abbvie Inc Prostatic Neoplasms Details
Anti-PSMA CAR T-cell therapy (TNK Therapeutics) Phase 1 Clinical Sorrento Therapeutics Inc Neoplasms Details
CART-PSMA-TGFβRDN cell therapy (Tmunity Therapeutics) TmPSMA-02 Phase 1 Clinical University Of Minnesota, University Of Pennsylvania Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
177Lu-PSMA-0057 177Lu-PSMA-0057 Nanjing First Hospital, Nanjing Medical University Details
[68Ga]Ga-PSMA-D5 [68Ga]Ga-PSMA-D5 Anhui Provincial Hospital Details
18F-PSMA-1007 18F-PSMA-1007 Phase 3 Clinical Deutsches Krebsforschungszentrum Neoplasms; Prostatic Neoplasms Details
Gallium-68 PSMA-617 225 Ac-PSMA-617; 68Ga-PSMA-617; 68Ga-DKFZ-617; 68Ga-DKFZ-PSMA -617; Gallium-68-PSMA-617; PSMA-617-[68Ga]; 68Ga-DOTA-PSMA-DKFZ -617 Phase 3 Clinical Peking Union Medical College Hospital Carcinoma, Adenoid Cystic; Prostatic Neoplasms Details
Fluorine-18-CTT-1057 CTT-1057; 18F-CTT1057; CTT-1057-18F; CTT-1057-F-18 Phase 3 Clinical Washington University, Cancer Targeted Technology Llc Recurrence; Carcinoma, Renal Cell; Prostatic Neoplasms Details
ITM-24D ITM-24D; 68Ga-PSMA-TTM Phase 3 Clinical ITM Isotope Technologies Munich SE Prostatic Neoplasms Details
18F vipivotide tetraxetan 18F-PSMA-617; Al18F-PSMA-617 Phase 3 Clinical Peking Union Medical College Hospital Prostatic Neoplasms Details
64Cu-PSMA I&T Copper Cu 64 PSMA I&T; Cu-64-PSMA-I&T; 64-Copper-PSMA-I&T; Copper-64-prostate specific membrane antigen I&T Phase 3 Clinical Curium Us Llc Prostatic Neoplasms Details
Thretide[18F] Phase 3 Clinical Shanghai Lannacheng Biotechnology Co Ltd Neoplasms; Prostatic Neoplasms; Diagnostic agents Details
64Cu-SAR-bisPSMA (Clarity Pharmaceuticals) Phase 3 Clinical Clarity Pharmaceuticals Ltd Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
177Lu-DOTA-rosopatamb 177Lu-DOTA-TLX591-CHO; TLX591 Phase 3 Clinical Telix Pharmaceuticals Ltd Prostatic Neoplasms Details
[Lu177]-PNT-2002 PNT-2002 Phase 3 Clinical Carcinoma, Adenoid Cystic; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
Lutetium-177-PSMA-I&T Phase 2 Clinical Radboud University Nijmegen Salivary Gland Neoplasms; Carcinoma, Adenoid Cystic; Prostatic Neoplasms Details
68Ga-PSMA-R2 (Advanced Accelerator Applications SA) Phase 2 Clinical Advanced Accelerator Applications Sa Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
177Lu-PSMA-R2 177Lu-PSMA-R2; 177Lu-PSMA-SR6; AAA-602 Phase 2 Clinical Advanced Accelerator Applications Sa Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
89Zr-DFO-huJ591 Zr89-J591; 89Zr-DFO-J591; 89Zr-DFO-huJ591 Phase 2 Clinical Memorial Sloan Kettering Cancer Center Prostatic Neoplasms Details
Nezastomig REGN-5678 Phase 2 Clinical Carcinoma, Renal Cell; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
225Ac-J591 225Ac-DOTA-J591; 225Ac-J591; CONV 01-α Phase 2 Clinical Cornell University Prostatic Neoplasms Details
ATL-101 MLN-591RL; ATL-101; huJ-591; MLN-591; J-591; Lu-177-J591; 177Lu-J591; 90Y-J591; muJ-591 Phase 2 Clinical Weill Medical College of Cornell University Ovarian Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung Details
[131I]MIP-1095 1095; [131I]MIP-1095; [131I]MIP-1466 Phase 2 Clinical Progenics Pharmaceuticals Inc Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
CONV-01-alpha + PSMA I&T Phase 2 Clinical Convergent Therapeutics Inc Prostatic Neoplasms Details
LAVA-1207 LAVA-1207 Phase 2 Clinical Vu University Medical Center, Lava Therapeutics NV Prostatic Neoplasms, Castration-Resistant Details
4SCAR-PSMA T cell therapy (Shenzhen Geno-Immune Medical Institute) Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Lymphoma, B-Cell; Neoplasms Details
[225Ac]Ac-PSMA-R2 [225Ac]Ac-PSMA-R2 Phase 2 Clinical Novartis Pharma Ag Prostatic Neoplasms, Castration-Resistant Details
177Lu-PSMA 177Lu-PSMA Phase 2 Clinical Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori Carcinoma, Renal Cell; Neoplasms; Prostatic Neoplasms; Neoplasm Metastasis Details
[177Lu]JH020002 Lu 177 JH020002; [177Lu]JH020002; 177-Lu JH-020002 Phase 2 Clinical Bivision Biomedical Technology (Nanjing) Co Ltd Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
[177Lu]Lu-XT033 [177Lu]Lu-XT033 Phase 2 Clinical Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
177Lu-HTK03170 177Lu-HTK03170 Phase 2 Clinical British Columbia Cancer Agency Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
Ga-68-NGUL Phase 2 Clinical Cellbion Co Ltd Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Lymphoma, B-Cell; Leukemia, B-Cell Details
GD2/PSMA Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) bi-4SCAR GD2/PSMA Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Solid tumours Details
PSMA/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) bi-4SCAR PSMA/CD70 Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Neoplasms Details
177Lu-rhPSMA-10.1 177Lu-rhPSMA10.1; (177Lu) rhPSMA-10.1; Lutetium (177Lu) rhPSMA-10.1 (Tx IMP); Lutetium-177 rhPSMA10.1; Lutetium Lu 177 PSMA-10.1; 177Lu rhPSMA-10.1; Lu177-rhPSMA; 177Lu Radiohybrid PSMA-10.1; 177Lu-rhPSMA-10.1; 177Lu-rhPSMA Phase 2 Clinical Technical University Munich Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Urogenital Neoplasms; Prostatic Diseases Details
Lu-177-DGUL PSMA-D GUL; Lu-177-DGUL; 177Lu-DOTA-GUL Phase 2 Clinical Cellbion Co Ltd Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
TLX-592 TLX-592 Phase 2 Clinical Telix Pharmaceuticals Ltd Prostatic Neoplasms Details
68Ga-PSMA-IRDye TLX591-Sx Phase 2 Clinical Telix Pharmaceuticals Ltd Prostatic Neoplasms Details
REGN-4336 REGN-4336 Phase 2 Clinical Prostatic Neoplasms, Castration-Resistant Details
[177Lu]Ludotadipep 177Lu-FC705; 177Lu-FC-705 Phase 2 Clinical Futurechem Prostatic Neoplasms, Castration-Resistant Details
67Cu-SAR-bisPSMA (Clarity Pharmaceuticals) Phase 2 Clinical Clarity Pharmaceuticals Ltd Prostatic Neoplasms, Castration-Resistant Details
ARX-517 ARX-517; ARX517 Phase 2 Clinical Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
OTL-78 OTL-78 Phase 2 Clinical Purdue University, Novartis Pharma Ag Prostatic Neoplasms Details
INO-5401 INO-5401 Phase 2 Clinical Inovio Pharmaceuticals Inc Carcinoma, Transitional Cell; Glioblastoma Details
225 Actinium PSMA-617 225 Actinium PSMA-617; 225Ac-PSMA 617; AAA 817; 225Ac-PSMA-617 Phase 1 Clinical Novartis Pharma Ag, Endocyte Inc, Advanced Accelerator Applications Sa Prostatic Neoplasms, Castration-Resistant Details
JNJ-63898081 JNJ-8081; JNJ-63898081 Phase 1 Clinical Johnson & Johnson Innovative Medicine Neoplasms Details
P28z-CAR P28z-CAR Phase 1 Clinical Memorial Sloan Kettering Cancer Center, United States Department Of Defense Prostatic Neoplasms Details
PSMA-CART cell therapy (Shanghai Bioray Laboratory) Phase 1 Clinical BRL Medicine Inc Prostatic Neoplasms, Castration-Resistant Details
Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center Phase 1 Clinical Roger Williams Medical Center Prostatic Neoplasms Details
CC-1 CC-1 Phase 1 Clinical University Of Tubingen, German Cancer Research Center (Dkfz) Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Carcinoma, Squamous Cell Details
Acapatamab AMG-160 Phase 1 Clinical Amgen Inc Prostatic Neoplasms, Castration-Resistant; Carcinoma, Non-Small-Cell Lung Details
177Lu-EB-vipivotide tetraxetan 177-Lu-EB-PSMA-617 Phase 1 Clinical Peking Union Medical College Hospital, National Institute For Biomedical Imaging And Bioengineering (Nibib) Carcinoma, Renal Cell; Carcinoma, Adenoid Cystic; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
[177Lu]-CTT-1403 CTT-1403; [177Lu]CTT1403; 177Lutetium CTT1403; [177Lu]CTT-1403 Phase 1 Clinical Cancer Targeted Technology Llc Prostatic Neoplasms Details
Pelgifatamab corixetan BAY-2315497 Phase 1 Clinical Bayer AG Prostatic Neoplasms, Castration-Resistant Details
161Tb-SibuDAB Phase 1 Clinical University Hospital Basel Prostatic Neoplasms, Castration-Resistant Details
[Ac-225]-PSMA-62 [Ac-225]-PSMA-62 Phase 1 Clinical Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
JNJ-9401 JNJ-9401 Phase 1 Clinical Xencor Inc Prostatic Neoplasms Details
ABBV-969 ABBV-969; ABBV969 Phase 1 Clinical Abbvie Inc, Immunogen Inc Prostatic Neoplasms, Castration-Resistant Details
JNJ-87189401 JNJ-87189401 Phase 1 Clinical Janssen Research & Development Llc Prostatic Neoplasms Details
Actinium-225-macropa-pelgifatamab BAY-3546828; BAY3546828 Phase 1 Clinical Bayer AG Prostatic Neoplasms, Castration-Resistant Details
177Lu-LNC1003 177Lu-LNC1003 Phase 1 Clinical Shanghai Lannacheng Biotechnology Co Ltd Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
PSMA-Targeted [In-111]-Labeled Trillium Compound Phase 1 Clinical Ratio Therapeutics Inc Prostatic Neoplasms Details
Autologous T cells therapy(Unicar-Therapy) Phase 1 Clinical Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Prostatic Neoplasms Details
212Pb-NG001 212Pb-NG001; AB-001; AB001 Phase 1 Clinical ARTBIO Inc Prostatic Neoplasms, Castration-Resistant Details
CART-PSMA cells（Nova Therapeutics） Phase 1 Clinical Nova Therapeutics LLC Prostatic Neoplasms Details
68Ga-labeled NY108 68-Ga-labeled NY-108 Phase 1 Clinical Prostatic Neoplasms Details
JANX-007 JANX-007; PSMA-TRACTr Phase 1 Clinical Janux Therapeutics Inc Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
JNJ-80038114 JNJ-80038114 Phase 1 Clinical Janssen Research & Development Llc Prostatic Neoplasms Details
CART-PSMA-TGFbRDN (University of Pennsylvania) Phase 1 Clinical University Of Pennsylvania Prostatic Neoplasms Details
TNB-585 TNB-585; AMG-340 Phase 1 Clinical Teneobio Inc Prostatic Neoplasms, Castration-Resistant Details
AVC-102 AVC-102 Phase 1 Clinical AvenCell Therapeutics Inc Kidney Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung Details
CBP-1018 CBP-1018 Phase 1 Clinical Solid tumours; Carcinoma, Renal Cell; Prostatic Neoplasms; Lung Neoplasms Details
CCW-702 CCW-702 Phase 1 Clinical The Scripps Research Institute Inc, Abbvie Inc Prostatic Neoplasms Details
Anti-PSMA CAR T-cell therapy (TNK Therapeutics) Phase 1 Clinical Sorrento Therapeutics Inc Neoplasms Details
CART-PSMA-TGFβRDN cell therapy (Tmunity Therapeutics) TmPSMA-02 Phase 1 Clinical University Of Minnesota, University Of Pennsylvania Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms Details
177Lu-PSMA-0057 177Lu-PSMA-0057 Nanjing First Hospital, Nanjing Medical University Details
[68Ga]Ga-PSMA-D5 [68Ga]Ga-PSMA-D5 Anhui Provincial Hospital Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook youtube

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap